Literature DB >> 22228310

Measurement of oxidative stress and endothelial dysfunction in patients with hypopituitarism and severe deficiency adult growth hormone deficiency.

Daniel González-Duarte1, Ainara Madrazo-Atutxa, Alfonso Soto-Moreno, Alfonso Leal-Cerro.   

Abstract

Patients with adult GH deficiency (AGHD) have a high cardiovascular risk and probably an alteration of the oxidative balance, although evidence is lacking. To evaluate the presence of endothelial dysfunction and oxidative stress in patients with AGHD. Biochemical parameters of oxidative stress and endothelial dysfunction were compared in 25 patients with previously untreated AGHD and 25 healthy controls matched by age and sex. Multivariate analysis was performed to identify independent predictors of oxidative stress. Vascular function of subcutaneous resistance arteries was also analyzed by means of wire myography in 7 patients with untreated AGHD and in 7 healthy controls with similar characteristics. The values of C-reactive protein, interleukin-6 (IL-6) and tumour necrosis factor alpha (TNF-α), were higher in the AGHD group (4.6 vs. 0.2 μg/L, P = 0.02; 5.6 vs. 1.2 pg/mL, P = 0.001; 6.7 vs. 2.1 pg/mL, P = 0.04; respectively). The levels of type-1 vascular cell adhesion molecule, total anti-oxidant state, oxidized LDL (LDL-ox) were also greater in AGHD patients (678 vs. 423 ng/mL, P = 0.004; 1235.6 vs. 1002.3 μmol/L, P = 0.01; 172.2.5 vs. 42.3 ng/mL, P = 0.02; respectively). Nitric oxide (NO), reduced glutathione (GSH) and reduced/oxidized glutathione ratio (GSH/GSSG) values were lower than controls (18.7 vs. 31.6 mmol/mg protein, P = 0.01; 372.2 vs. 756.2 μmol/L, P = 0.03; 17.2 vs. 38.4, P = 0.04; respectively). Multiple regression analysis showed that AGHD was an independent predictor of increased LDL-ox (P = 0.002) and decreased GSH (P = 0.000). Furthermore, the degree of vascular relaxation to repeated exposure of acetylcholine was lower in AGHD (P = 0.025). Patients with AGHD have an increased degree of oxidative stress and endothelial dysfunction that could already be present in early stages of the disease. Studies with a greater number of patients are needed in order to confirm our findings.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22228310     DOI: 10.1007/s11102-011-0374-4

Source DB:  PubMed          Journal:  Pituitary        ISSN: 1386-341X            Impact factor:   4.107


  23 in total

1.  Increased lipid peroxidation in adult GH-deficient patients: effects of short-term GH administration.

Authors:  M Scacchi; E Valassi; A I Pincelli; L M Fatti; F Pecori Giraldi; P Ascoli; R Viarengo; B Cestaro; F Cavagnini; R Cazzola
Journal:  J Endocrinol Invest       Date:  2006-11       Impact factor: 4.256

2.  The growth hormone (GH) response to the arginine plus GH-releasing hormone test is correlated to the severity of lipid profile abnormalities in adult patients with GH deficiency.

Authors:  A Colao; G Cerbone; R Pivonello; G Aimaretti; S Loche; C Di Somma; A Faggiano; G Corneli; E Ghigo; G Lombardi
Journal:  J Clin Endocrinol Metab       Date:  1999-04       Impact factor: 5.958

3.  Oxidized forms of glutathione in peripheral blood as biomarkers of oxidative stress.

Authors:  Ranieri Rossi; Isabella Dalle-Donne; Aldo Milzani; Daniela Giustarini
Journal:  Clin Chem       Date:  2006-05-11       Impact factor: 8.327

Review 4.  Beginning to end: cardiovascular implications of growth hormone (GH) deficiency and GH therapy.

Authors:  Annamaria Colao; Carolina Di Somma; Maria Cristina Savanelli; Monica De Leo; Gaetano Lombardi
Journal:  Growth Horm IGF Res       Date:  2006-05-11       Impact factor: 2.372

5.  Role of nitric oxide in the vasodilator effect of recombinant human growth hormone in patients with dilated cardiomyopathy.

Authors:  K J Osterziel; S M Bode-Böger; O Strohm; A E Ellmer; N Bit-Avragim; D Hänlein; M B Ranke; R Dietz; R H Böger
Journal:  Cardiovasc Res       Date:  2000-01-14       Impact factor: 10.787

6.  Nitric oxide, prostanoid and non-NO, non-prostanoid involvement in acetylcholine relaxation of isolated human small arteries.

Authors:  N H Buus; U Simonsen; H K Pilegaard; M J Mulvany
Journal:  Br J Pharmacol       Date:  2000-01       Impact factor: 8.739

7.  Growth hormone (GH) treatment reverses early atherosclerotic changes in GH-deficient adults.

Authors:  M Pfeifer; R Verhovec; B Zizek; J Prezelj; P Poredos; R N Clayton
Journal:  J Clin Endocrinol Metab       Date:  1999-02       Impact factor: 5.958

8.  Positive effects of a physiological dose of GH on markers of atherogenesis: a placebo-controlled study in patients with adult-onset GH deficiency.

Authors:  Jens Bollerslev; Thor Ueland; Anders P Jørgensen; Kristian J Fougner; Ragnhild Wergeland; Thomas Schreiner; Pia Burman
Journal:  Eur J Endocrinol       Date:  2006-04       Impact factor: 6.664

9.  Lack of evidence of premature atherosclerosis in untreated severe isolated growth hormone (GH) deficiency due to a GH-releasing hormone receptor mutation.

Authors:  Joselina Luzia Menezes Oliveira; Celi Marques-Santos; José Augusto Barreto-Filho; Roberto Ximenes Filho; Allan Valadão de Oliveira Britto; Anita Hermínia Oliveira Souza; Clarisse Miranda Prado; Carla Raquel Pereira Oliveira; Rossana Maria C Pereira; Tábita de Almeida Ribeiro Vicente; Catarine Teles Farias; Manuel Hermínio Aguiar-Oliveira; Roberto Salvatori
Journal:  J Clin Endocrinol Metab       Date:  2006-03-07       Impact factor: 5.958

10.  Growth hormone replacement reduces C-reactive protein and large-artery stiffness but does not alter endothelial function in patients with adult growth hormone deficiency.

Authors:  Roland W McCallum; Christopher A R Sainsbury; Angela Spiers; Anna F Dominiczak; John R Petrie; Naveed Sattar; John M C Connell
Journal:  Clin Endocrinol (Oxf)       Date:  2005-04       Impact factor: 3.478

View more
  5 in total

1.  Increase in serum pregnancy-associated plasma protein-A is correlated with increase in cardiovascular risk factors in adult patients with growth hormone deficiency.

Authors:  Linman Li; Wei Ren; Jinchao Li; Jingjing Liu; Lingli Wang; Xiaoya Zheng; Dezhen Liu; Sufang Li; Rhonda Souvenir; Jiping Tang
Journal:  Endocrine       Date:  2012-05-29       Impact factor: 3.633

2.  Imbalance in the blood antioxidant system in growth hormone-deficient children before and after 1 year of recombinant growth hormone therapy.

Authors:  Maria S Pankratova; Adil A Baizhumanov; Alexander I Yusipovich; Maria Faassen; Tatyana Yu Shiryaeva; Valentina A Peterkova; Svetlana S Kovalenko; Tatiana A Kazakova; Georgy V Maksimov
Journal:  PeerJ       Date:  2015-06-25       Impact factor: 2.984

Review 3.  Beta-thalassemia major and female fertility: the role of iron and iron-induced oxidative stress.

Authors:  Paraskevi Roussou; Nikolaos J Tsagarakis; Dimitrios Kountouras; Sarantis Livadas; Evanthia Diamanti-Kandarakis
Journal:  Anemia       Date:  2013-12-16

4.  Reduced peak stimulated growth hormone is associated with hyperuricemia in obese children and adolescents.

Authors:  Shuang Liang; Dejian Zhang; Jianhong Qi; Xiaobo Song; Jiang Xue
Journal:  Sci Rep       Date:  2018-05-21       Impact factor: 4.379

5.  Can plasma antioxidants prevent DNA damage in oxidative stress condition induced by growth hormone deficiency? A pilot study.

Authors:  Antonio Mancini; Francesco Guidi; Carmine Bruno; Flavia Angelini; Edoardo Vergani; Paola Lanza; Alvaro Mordente; Elisabetta Meucci; Andrea Silvestrini
Journal:  PLoS One       Date:  2021-04-01       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.